Amgen Beheer

Beheer criteriumcontroles 3/4

De CEO Amgen is Bob Bradway, benoemd in May2010, heeft een ambtstermijn van 14.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 22.64M, bestaande uit 7.9% salaris en 92.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.12% van de aandelen van het bedrijf, ter waarde R$ 1.07B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.8 jaar en 7.9 jaar.

Belangrijke informatie

Bob Bradway

Algemeen directeur

US$22.6m

Totale compensatie

Percentage CEO-salaris	7.9%
Dienstverband CEO	14.5yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	4.8yrs
Gemiddelde ambtstermijn bestuur	7.9yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Bob Bradway's beloning veranderd ten opzichte van Amgen's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$4b
Jun 30 2024	n/a	n/a	US$3b
Mar 31 2024	n/a	n/a	US$4b
Dec 31 2023	US$23m	US$2m	US$7b
Sep 30 2023	n/a	n/a	US$8b
Jun 30 2023	n/a	n/a	US$8b
Mar 31 2023	n/a	n/a	US$8b
Dec 31 2022	US$21m	US$2m	US$7b
Sep 30 2022	n/a	n/a	US$7b
Jun 30 2022	n/a	n/a	US$7b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$22m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$7b
Dec 31 2020	US$20m	US$2m	US$7b
Sep 30 2020	n/a	n/a	US$7b
Jun 30 2020	n/a	n/a	US$7b
Mar 31 2020	n/a	n/a	US$8b
Dec 31 2019	US$20m	US$2m	US$8b
Sep 30 2019	n/a	n/a	US$8b
Jun 30 2019	n/a	n/a	US$8b
Mar 31 2019	n/a	n/a	US$8b
Dec 31 2018	US$19m	US$2m	US$8b
Sep 30 2018	n/a	n/a	US$2b
Jun 30 2018	n/a	n/a	US$2b
Mar 31 2018	n/a	n/a	US$2b
Dec 31 2017	US$17m	US$2m	US$2b

Compensatie versus markt: De totale vergoeding ($USD 22.64M ) Bob } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de BR markt ($USD 5.75M ).

Compensatie versus inkomsten: De vergoeding van Bob is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Bob Bradway (61 yo)

14.5yrs

Tenure

US$22,643,650

Compensatie

Mr. Robert A. Bradway, also known as Bob, has been the Chief Executive Officer of Amgen Inc. since May 23, 2012 and has been its President since May 2010. Mr. Bradway is responsible for the Amgen's global...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Bradway	Chairman	14.5yrs	US$22.64m	0.12% R$ 1.1b
Peter Griffith	Executive VP & CFO	4.8yrs	US$7.57m	0.0046% R$ 42.4m
Esteban Santos	Executive Vice President of Operations	8.3yrs	US$7.21m	0.011% R$ 105.0m
David Reese	Executive VP & CTO	less than a year	US$7.90m	0.0094% R$ 86.3m
Murdo Gordon	Executive Vice President of Global Commercial Operations	6.2yrs	US$8.24m	0.0075% R$ 68.6m
Matthew Busch	Chief Accounting Officer & VP of Finance	1.3yrs	geen gegevens	0.00062% R$ 5.7m
James Bradner	Executive VP of Research & Development and Chief Scientific Officer	less than a year	geen gegevens	geen gegevens
Scott Skellenger	Senior VP & Chief Information Officer	no data	geen gegevens	geen gegevens
Justin Claeys	Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Jonathan Graham	Executive VP	9.3yrs	US$7.24m	0.0046% R$ 42.7m
Nancy Grygiel	Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer	4.8yrs	geen gegevens	0.0013% R$ 12.0m
Kave Niksefat	Senior Vice President of Global Marketing & Access	less than a year	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van AMGN34 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Bradway	Chairman	13.1yrs	US$22.64m	0.12% R$ 1.1b
Robert Eckert	Lead Independent Director	11.9yrs	US$419.92k	0.0013% R$ 12.0m
David Baltimore	Co-Chair of Scientific Advisory Board	no data	US$292.01k	geen gegevens
Charles Sigal	Co-Chair of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Amy Miles	Independent Director	4.3yrs	US$359.92k	0.000080% R$ 735.3k
Charles Holley	Independent Director	7.8yrs	US$369.92k	0.00023% R$ 2.1m
Greg Garland	Independent Director	11.1yrs	US$379.92k	0.0023% R$ 21.1m
Ellen Kullman	Independent Director	8.1yrs	US$360.29k	0.000080% R$ 735.3k
Brian Druker	Independent Director	6.5yrs	US$359.92k	0.00015% R$ 1.4m
Tyler Jacks	Independent Director	12.5yrs	US$339.92k	0.00051% R$ 4.7m
Wanda Austin	Independent Director	6.9yrs	US$359.92k	0.0012% R$ 11.2m
S. Ishrak	Independent Director	3.3yrs	US$366.47k	0.00017% R$ 1.6m

7.9yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AMGN34 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.9 jaar).

Amgen Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Howard Chang Joins Amgen as Senior Vice President of Research and Chief Scientific Officer, Effective December 16, 2024

Amgen Inc. Appoints Anumita Tripathi as Director of Corporate Affairs for Amgen India

Amgen Inc., Annual General Meeting, May 31, 2024

Amgen Inc. Announces Executive Changes

Amgen Inc. Announces Management Changes

Recent updates

Howard Chang Joins Amgen as Senior Vice President of Research and Chief Scientific Officer, Effective December 16, 2024

Amgen and AstraZeneca Announce Positive Top-Line Results from the Phase 3 WayPOINT Trial in Patients with Chronic Rhinosinusitis with Nasal Polyps

Amgen Inc. Provides Earnings Guidance for the Full Year 2024

Amgen Inc. Announces Dividend for the Fourth Quarter of 2024, Payable on December 9, 2024

Amgen Inc. to Report Q3, 2024 Results on Oct 30, 2024

Amgen Announces Presents Positive Top-Line Results from the Phase 3 MINT Trial Evaluating the Efficacy and Safety of UPLIZNA

Amgen Inc. Appoints Anumita Tripathi as Director of Corporate Affairs for Amgen India

Amgen Announces Otezla®? (Apremilast) Now Available in the U.S. for Moderate to Severe Plaque Psoriasis

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q2, 2024 Results on Aug 06, 2024

Amgen Inc. Announces U.S. Food and Drug Administration Approves Blincyto

Amgen Announces Positive Results for Phase 3 Registrational Trial Evaluating Uplizna® (Inebilizumab-Cdon) for Treatment of Immunoglobulin G4-Related Disease (Igg4-Rd)

FDA Approves Amgen's IMDELLTRA™? (Tarlatamab-Llle) for the Treatment of Adult Patients with Extensive-Stage Small Cell Lung Cancer

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q1, 2024 Results on May 02, 2024

Amgen to Submits Marketing Authorization Application to the European Medicines Agency

Amgen Inc., Annual General Meeting, May 31, 2024

Amgen Presents New Research on Otezla (Apremilast) at AAD 2024

Amgen Announces 2024 Second Quarter Dividend, Payable on June 7,2024

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q4, 2023 Results on Feb 06, 2024

Amgen Provides Regulatory Update on Status of LUMAKRAS (Sotorasib)

Amgen Inc. Announces Executive Changes

Amgen Presents New Data from Phase 2 Trial of Dazodalibep in Sjogren's Syndrome at ACR 2023

Amgen Inc. Presents New Data That Show Blood Pressure Decides for Results Treated with Krystexxa (PegLOTICase)

Amgen Inc. Provides Earnings Guidance for the Full Year 2023

Amgen Inc. to Report Q3, 2023 Results on Oct 31, 2023

Amgen Inc. Declares Dividend for the Fourth Quarter of 2023, Payable on December 8, 2023

Amgen Presents New LUMAKRAS (Sotorasib) Plus Vectibix (Panitumumab) Data in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer

Amgen Inc. to Present New Research from Oncolfolio and Pipeline At ESMO2023

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Amgen Presents New Lumakras® (Sotorasib) Plus Chemotherapy Data in First-Line Kras G12c Nsclc At Wclc

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen Presents Phase 2 OLPASIRan Data at ESC 2023

Amgen Announces to Discuss Application for LUMAKRAS (Sotorasib) for Treatment of KRAS G12C-Positive NSCLC at FDA Advisory Committee Meeting

Amgen Inc. Announces Management Changes

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2023

Amgen Inc. to Report Q2, 2023 Results on Aug 03, 2023

Amgen Inc. Announces U.S. Food and Drug Administration Approves Supplemental Biologics License Application for BLINCYTO

Amgen Presents New Lumakras® (Sotorasib) Codebreak 200 CNS Data At Asco 2023

Amgen Presents New Scientific and Clinical Research Across its Diverse Oncology Portfolio and Pipeline at ASCO 2023

Amgen Presents New Research on Otezla® (Apremilast) in Psoriatic Arthritis At Eular 2023

Amgen Inc. Announces New Data from A Real-World Study of Nearly Half of Million Postmenopausal Women with Osteoporosis in the U.S. Medicare Program

AstraZeneca and Amgen Announce Approval of TEZSPIRE® (tezepelumab-ekko) in the US

Amgen Inc. to Report Q4, 2022 Results on Jan 31, 2023

Amgen Announces ECOG-ACRIN Cancer Research Group Results

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd